Sab Biotherapeutics, Inc. · NASDAQ:SABS
Balyasny Asset Management L.P. reported a 9.45% stake in Sab Biotherapeutics, Inc. (Schedule 13G/A)
Event Jun 30, 2026 · Filed Aug 14, 2026
Balyasny Asset Management L.P. reported a 9.45% stake in Sab Biotherapeutics, Inc., 7,225,439 shares, as a passive investor on Jun 30, 2026. Filed Aug 14, 2026 (Schedule 13G/A).
- Stake
- 9.45%
- Shares
- 7,225,439
- Intent
- Passive
- What changed
- Stake changed
- Filed together
- 5 holders
The filing in full
| Holder | Stake | Shares |
|---|---|---|
| BALYASNY ASSET MANAGEMENT L.P. | 9.45% | 7,225,439 |
| BAM GP LLC | 9.45% | 7,225,439 |
| Balyasny Asset Management Holdings LP | 9.45% | 7,225,439 |
| Dames GP LLC | 9.45% | 7,225,439 |
| Dmitry Balyasny | 9.45% | 7,225,439 |
Source
Related
- Sab Biotherapeutics, Inc.
- Balyasny Asset Management L.P.
- Sab Biotherapeutics, Inc. shareholders
- Schedule 13G · Balyasny Asset Management L.P. · May 15, 2026
- Form 4 · Kropotova Alexandra · Sep 18, 2026
- Schedule 13G/A · Vivo Opportunity, LLC · Aug 14, 2026
- Schedule 13G/A · Woodline Partners LP · Aug 14, 2026
- Schedule 13G/A · Caligan Partners LP · Aug 14, 2026
- Schedule 13G/A · Commodore Capital LP · Aug 14, 2026